the added value of early detection and interception in patients with myeloma
Published 2 years ago • 126 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
1:49
the value of mass spectrometry in multiple myeloma & how this may impact clinical practice
-
2:37
meta-analysis of studies on biomarker-defined early multiple myeloma
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
3:46
a phase ib/ii trial of sonrotoclax plus dexamethasone in patients with r/r mm harboring t(11;14)
-
1:22
an all-molecular diagnostic approach for myeloma
-
1:53
the future of multiple myeloma treatment
-
1:01
an update on the phase i trial of bms-986393, a novel gprc5d-targeted car-t, in r/r myeloma
-
2:23
the significance of variant allele frequency in patients with sf3b1-mutated mds
-
56:57
hematopathology: flow cytometry and acute leukemias
-
8:48
whole body mri: an update
-
0:52
imroz trial updates: isa-vrd versus vrd in patients with ndmm ineligible for transplant
-
1:40
updates on the use of molecular monitoring to detect mrd in aml
-
4:01
kenneth anderson: what are the next steps to a myeloma cure?
-
2:20
ultra high-risk myeloma
-
1:55
diagnosing and treating aml: the role of mutational profiling
-
1:21
what is the pcrowd study, and how does knowledge in myeloma biology help with new treatments?
-
0:58
patient-reported outcomes from the dreamm-8 trial of belantamab mafodotin in multiple myeloma
-
1:37
mrd in myeloma
-
3:35
myeloma global trends: gross underestimation
-
1:37
the next steps and updated guidelines for the use of mrd concepts in multiple myeloma
-
3:01
treatment approaches for asct-eligible myeloma patients in the frontline